Suppr超能文献

糖尿病视网膜病变早期治疗研究中的玻璃体切除术。ETDRS报告第17号。糖尿病视网膜病变早期治疗研究研究组。

Pars plana vitrectomy in the Early Treatment Diabetic Retinopathy Study. ETDRS report number 17. The Early Treatment Diabetic Retinopathy Study Research Group.

作者信息

Flynn H W, Chew E Y, Simons B D, Barton F B, Remaley N A, Ferris F L

机构信息

Department of Ophtalmology, Bascom Palmer Eye Institute, University of Miami School of Medicine.

出版信息

Ophthalmology. 1992 Sep;99(9):1351-7. doi: 10.1016/s0161-6420(92)31779-8.

Abstract

BACKGROUND

The Early Treatment Diabetic Retinopathy Study (ETDRS) enrolled 3711 patients with mild-to-severe nonproliferative or early proliferative diabetic retinopathy in both eyes. Patients were randomly assigned to aspirin 650 mg/day or placebo. One eye of each patient was assigned randomly to early photocoagulation and the other to deferral of photocoagulation. Follow-up examinations were scheduled at least every 4 months, and photocoagulation was initiated in eyes assigned to deferral as soon as high-risk proliferative retinopathy was detected. Aspirin was not found to have an effect on retinopathy progression or rates of vitreous hemorrhage. The risk of a combined end point, severe visual loss or vitrectomy, was low in eyes assigned to deferral (6% at 5 years) and was reduced by early photocoagulation (4% at 5 years). Vitrectomy was carried out in 208 patients during the 9 years of the study. This report presents baseline and previtrectomy characteristics and visual outcome in these patients.

METHODS

Information collected at baseline and during follow-up as part of the ETDRS protocol was supplemented by review of clinic charts for visual acuity and ocular status immediately before vitrectomy.

RESULTS

Vitrectomy was performed in 208 (5.6%) of the 3711 patients (243 eyes) enrolled in the ETDRS. The 5-year vitrectomy rates for eyes grouped by their initial photocoagulation assignment were as follows: 2.1% in the early full scatter photocoagulation group, 2.5% in the early mild scatter group, and 4.0% in the deferral group. The 5-year rates of vitrectomy (in one or both eyes) were 5.4% in patients assigned to aspirin and 5.2% in patients assigned to a placebo. The indications for vitrectomy were either vitreous hemorrhage (53.9%) or retinal detachment with or without vitreous hemorrhage (46.1%). Before vitrectomy, visual acuity was 5/200 or worse in 66.7% of eyes and better than 20/100 in 6.2%. One year after vitrectomy, the visual acuity was 20/100 or better in 47.6% of eyes, including 24.0% with visual acuity of 20/40 or better.

CONCLUSIONS

With frequent follow-up examinations and timely scatter (panretinal) photocoagulation, the 5-year cumulative rate of pars plana vitrectomy in ETDRS patients was 5.3%. Aspirin use did not influence the rate of vitrectomy.

摘要

背景

糖尿病视网膜病变早期治疗研究(ETDRS)纳入了3711例双眼患有轻度至重度非增殖性或早期增殖性糖尿病视网膜病变的患者。患者被随机分配至服用650毫克/天阿司匹林组或安慰剂组。每位患者的一只眼睛被随机分配至早期光凝治疗组,另一只眼睛被分配至延迟光凝治疗组。随访检查至少每4个月进行一次,一旦在延迟光凝治疗组的眼睛中检测到高危增殖性视网膜病变,即开始进行光凝治疗。未发现阿司匹林对视网膜病变进展或玻璃体出血发生率有影响。在延迟光凝治疗组的眼睛中,严重视力丧失或玻璃体切割术这一联合终点事件的风险较低(5年时为6%),而早期光凝治疗可降低该风险(5年时为4%)。在9年的研究期间,208例患者接受了玻璃体切割术。本报告介绍了这些患者的基线特征、玻璃体切割术前特征及视力转归情况。

方法

作为ETDRS方案一部分在基线和随访期间收集的信息,通过回顾玻璃体切割术前即刻的视力和眼部状况临床图表进行补充。

结果

ETDRS纳入的3711例患者(243只眼)中有208例(5.6%)接受了玻璃体切割术。根据初始光凝治疗分配分组的眼睛的5年玻璃体切割率如下:早期全视网膜光凝治疗组为2.1%,早期轻度视网膜光凝治疗组为2.5%,延迟光凝治疗组为4.0%。分配至阿司匹林组患者的5年玻璃体切割率(一只眼或双眼)为5.4%,分配至安慰剂组患者的为5.2%。玻璃体切割术的指征为玻璃体出血(53.9%)或伴有或不伴有玻璃体出血的视网膜脱离(46.1%)。在玻璃体切割术前,66.7%的眼睛视力为5/200或更差,6.2%的眼睛视力优于20/100。玻璃体切割术后1年,47.6%的眼睛视力为20/100或更好,其中24.0%的眼睛视力为20/40或更好。

结论

通过频繁的随访检查和及时的全视网膜光凝治疗,ETDRS患者的5年玻璃体切割术累积发生率为5.3%。使用阿司匹林不影响玻璃体切割术的发生率。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验